Publicaciones en las que colabora con Lydia Vela (39)

2023

  1. Cognitive impairment and dementia in young onset Parkinson’s disease

    Journal of Neurology, Vol. 270, Núm. 12, pp. 5793-5812

  2. Functional movement disorder comorbidity in Parkinson's disease: A multicenter descriptive study

    Parkinsonism and Related Disorders

  3. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden

    Brain and Behavior, Vol. 13, Núm. 12

2022

  1. Validation of the OPTIMIPARK Questionnaire: A Tool to Optimize Treatment in Parkinson's Disease

    Movement Disorders Clinical Practice, Vol. 9, Núm. 8, pp. 1085-1093

2021

  1. Predictors of clinically significant quality of life impairment in Parkinson’s disease

    npj Parkinson's Disease, Vol. 7, Núm. 1

2020

  1. Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders

    Brain, Vol. 143, Núm. 9, pp. 2771-2787

  2. Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease

    Journal of Parkinson's Disease, Vol. 10, Núm. 4, pp. 1611-1620

  3. Non-motor symptom burden in patients with Parkinson’s disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort

    Scientific Reports, Vol. 10, Núm. 1

  4. Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression

    Journal of the Neurological Sciences, Vol. 418

  5. Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information

    Nature Communications, Vol. 11, Núm. 1

  6. The impact of freezing of gait on functional dependency in Parkinson’s disease with regard to motor phenotype

    Neurological Sciences, Vol. 41, Núm. 10, pp. 2883-2892

2019

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

    European Journal of Neurology, Vol. 26, Núm. 11, pp. 1399-1407

  2. Creativity related to dopaminergic treatment: A multicenter study

    Parkinsonism and Related Disorders, Vol. 63, pp. 169-173

  3. High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients

    Journal of Neural Transmission, Vol. 126, Núm. 12, pp. 1599-1608

  4. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

    The Lancet Neurology, Vol. 18, Núm. 12, pp. 1091-1102

  5. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset

    npj Parkinson's Disease, Vol. 5, Núm. 1

  6. Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability

    npj Parkinson's Disease, Vol. 5, Núm. 1

  7. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort

    Parkinsonism and Related Disorders, Vol. 66, pp. 151-157

  8. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

    Movement Disorders, Vol. 34, Núm. 12, pp. 1851-1863

2018

  1. Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid

    Neurologia